Brad Loncar's Biotech Takeaways

Schwab Network

English - January 13, 2021 16:53 - 12 minutes - 56.9 MB - ★★★★★ - 23 ratings
News Commentary News Business News business news news commentary news Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Portfolio Risk Techniques For Investors

Next Episode: Stock Market Ahead of the Presidential Inauguration

Brad Loncar weighs in on Eli Lilly's (LLY) experimental Alzheimer's drug meeting primary endpoint of a small trial study. Also, the biggest deal at the JPM Conference was Beigene (BGNE) licensing a PD-1 cancer drug Tislelizumab.